Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viaskin Peanut in peanut-allergic children 1-3 years
NCT03211247Phase 3Completed
- Sponsor
- DBV Technologies
- Start
- Jul 2017
- Primary completion
- Aug 2019
- Modality
- Transdermal Patches
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of peanut protein in peanut allergy (5 arms), sponsored by DBV Technologies. Primary endpoint: Percentage of Treatment Responders at 12 months. Started Jul 2017; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03211247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211247.